Back to Careers
Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health
Back to Careers
Lilly Bites Again in $650M Muscle-Preserving Treatment Pact With Juvena
Back to Careers
Eli Lilly works out $650M Juvena pact to find muscle-boosting drugs
Back to Careers
Dr. Hanadie Yousef participates in the World Economic Forum’s Innovator Communities Meeting and Global Technology Retreat- and shares her expert insights on 2 panels: “Breaking Barriers: Funding Frontier Tech” and “Innovation to Impact: Commercialization Insights from the Field”
Back to Careers
CEO Dr. Hanadie Yousef discusses how the success of GLP-1/GIP receptor agonists is reshaping the treatment of chronic metabolic diseases and driving the next wave of therapeutics targeting the biology of aging at BIO 2025 in Boston
Back to Careers
CEO Dr. Hanadie Yousef joins a panel of industry leaders at BIO 2025 to explore how emerging therapeutic categories are reshaping dealmaking strategies, investment trends, and positioning in today’s evolving biotech landscape
Back to Careers
Juvena Therapeutics Announces Initiation of First-in-Human Clinical Trial of JUV-161
Back to Careers
Juvena Kicks Off First Human Trial of Muscle Regeneration Therapy
Back to Careers
Director of Translational Biology and Pharmacology, Priya Handa, PhD, and Senior Director of Discovery and Platform, Thach Mai, showcased our research at the 23rd Biopharma Drug Discovery Nexus Conference in San Francisco
Back to Careers
CEO Dr. Hanadie Yousef shares insights on a panel, “Entrepreneurial Excellence in BioPharma: Lessons from the Frontlines,” at SynBioBeta – The Global Synthetic Biology Conference in San Jose
